HFA-BDP and its implications for the quiet zone.
Tashkin
D P
DP
Department of Medicine, UCLA School of Medicine, Los Angeles, CA 90095-1690, USA. dtashkin@mednet.ucla.edu
D000287:Administration, Topical; D000335:Aerosol Propellants; D018927:Anti-Asthmatic Agents / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001249:Asthma / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001507:Beclomethasone / Q000494:pharmacology*; D001980:Bronchi / Q000187:drug effects*; D001995:Bronchography / Q000379:methods; D005938:Glucocorticoids; D006801:Humans; D006845:Hydrocarbons, Fluorinated; D014057:Tomography, X-Ray Computed / Q000379:methods*; D005466:Fluorocarbons
D000335:Aerosol Propellants; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D001507:Beclomethasone; D005938:Glucocorticoids; D006845:Hydrocarbons, Fluorinated; C094049:apaflurane; D005466:Fluorocarbons